Novavax’s flu data showcase vaccine platform’s potential

Pivotal data for Novavax’s flu vaccine provide validation of its recombinant nanoparticle vaccine platform as the biotech turns its technology towards developing a COVID-19 vaccine.

Novavax Inc. (NASDAQ:NVAX) added $2.01 (19%) to $12.77 Tuesday. This month, Novavax received $4 million from the Coalition for Epidemic Preparedness Innovations to develop a COVID-19 vaccine program and entered into a deal with Emergent BioSolutions Inc., which will supply Novavax with COVID-19 vaccine product for preclinical testing and for use in a Phase I trial (see “Novavax Secures $4M from CEPI”)...